{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-25-000002","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2025-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.964216+00:00","generated_at":"2026-05-27T04:47:08.399030+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Two Nautilus Biotechnology directors not standing for re-election at 2025 annual meeting","bullets":["Vijay Pande informed company on Jan 27, 2025, that he will not stand for re-election.","Michael Altman informed company on Jan 28, 2025, that he will not stand for re-election.","Both directors confirmed departure is not due to any disagreement with company operations, policies, or practices."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-25-000002","json":"https://secwatch.observer/filing/0001808805-25-000002.json","markdown":"https://secwatch.observer/filing/0001808805-25-000002.md","text":"https://secwatch.observer/filing/0001808805-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000002/0001808805-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000002/naut-20250127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:47:08.399030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10537a29e5","claim":"Michael Altman departed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000002/0001808805-25-000002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"informed that they will not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"935609445b","claim":"Vijay Pande departed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000002/0001808805-25-000002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"informed that they will not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}